Engene Therapeutics Inc. (ENGNW) Stock Price & Analysis
Engene Therapeutics Inc. (ENGNW) rose 0.00% to USD 0.23 as of September 9, 2026 at 12:43 UTC, according to Nexqual real-time market data.
ENGNW last closed at USD 0.23; the session ranged USD 0.22–0.23 on volume of 1,206 shares. Market capitalization is —, with a 52-week range of USD 0.22–0.23 (NCM). Source: Nexqual, September 9, 2026 at 12:43 UTC.
Key Statistics (as of September 9, 2026 at 12:43 UTC)
| Price | USD 0.23 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 0.23 |
| Open | USD 2.1 |
| Day Range | USD 0.22 – 0.23 |
| 52-Week Range | USD 0.22 – 0.23 |
| Volume | 1,206 shares |
| Market Cap | — |
| Exchange | NCM |
Analyst Ratings (ENGNW)
Wall Street analysts rate ENGNW "None", per Nexqual as of September 9, 2026 at 12:43 UTC.
| Consensus Rating | None |
|---|
Earnings (ENGNW)
| Revenue Estimate | $0 |
|---|
Source: Nexqual, September 9, 2026 at 12:43 UTC.
Financials & Fundamentals (ENGNW)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -52.59% |
| Debt / Equity | 13.07 |
| Current Ratio | 12.57 |
| Total Cash | $258.46M |
| Total Debt | $33.35M |
| Free Cash Flow | $-69.26M |
Source: Nexqual, September 9, 2026 at 12:43 UTC.
Financial Health Score (ENGNW)
Nexqual rates Engene Therapeutics Inc.'s overall financial health "Mixed" across five dimensions, as of September 9, 2026 at 12:43 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $258M cash vs $33M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$110M |
| Efficiency | Critical — ROE -53%, ROA -28.9% |
Ownership (ENGNW)
| Float | 32.73M |
|---|
Source: Nexqual, September 9, 2026 at 12:43 UTC.
Leadership (ENGNW)
Engene Therapeutics Inc. is led by Ronald H. W. Cooper (age 62), President, CEO & Director, per Nexqual as of September 9, 2026 at 12:43 UTC.
| President, CEO & Director | Ronald H. W. Cooper (age 62) |
|---|---|
| Interim Chief Medical Officer & Director | William J. Grossman (age 55) |
| Co-Founder & Chief Scientific Officer | Anthony T. Cheung (age 53) |
| Chief Technology Officer | Joan Connolly (age 55) |
Major Backers & Investors (ENGNW)
Notable institutional backers of Engene Therapeutics Inc. include FCPM III Services B.V., BVF Inc., Blue Owl Capital Holdings LP, according to Nexqual as of September 9, 2026 at 12:43 UTC.
Active Investors
| Investor | Stake |
|---|---|
| FCPM III Services B.V. | 28.76% |
| BVF Inc. | 9.45% |
| Blue Owl Capital Holdings LP | 5.11% |
| Caption Management, LLC | 3.33% |
| LMR Partners LLP | 3.1% |
| Aristeia Capital, LLC | 1.98% |
| Shaw D.E. & Co., Inc. | 1.05% |
| Toronto Dominion Bank | 0.32% |
Source: Nexqual, September 9, 2026 at 12:43 UTC.
From Engene Therapeutics Inc.'s Latest SEC 10-K Filing (filed 2025-12-22)
Key Strengths & Strategy (as disclosed to the SEC)
- enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada.
- The company develops genetic medicines to help patients suffering from bladder cancer.
- Its lead product candidate is detalimogene voraplasmid, a monotherapy for the treatment of non-muscle invasive bladder cancer (NMIBC).
- Its pipeline includes LEGEND, which is in Phase 2.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ENGN | enGene Therapeutics Inc. | USD 1.92 | ▲ 4.92% |
| DRTSW | Alpha Tau Medical Ltd. Warrant | USD 4.23 | ▲ 1.37% |
| ESLA | Estrella Immunopharma, Inc. | USD 0.64 | ▼ 0.16% |
| CDIOW | Cardio Diagnostics Holdings, Inc. | USD 0.02 | ▲ 0% |
| FBYDW | Falcon's Beyond Global, Inc. Wa | USD 0.95 | ▲ 6.54% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 9, 2026 at 12:43 UTC. This page is informational and not investment advice.